Probe compound as well as preparation method and application thereof
By designing fluorescent probe compounds of tetrastyrene derivatives and D-galactose residues, and using their isomers to react with β-Gal in senescent cells, the problem of insufficient recognition and removal of existing anti-aging drugs has been solved. Targeted clearance of senescent cells and effective treatment of osteoporosis have been achieved.
Patent Information
- Application Number
- CN202411189620.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-06
AI Technical Summary
Existing anti-aging drugs have poor recognition of senescent cells in the body, low sensitivity, and do not have the ability to remove, making it difficult to effectively treat aging-related osteoporosis.
A fluorescent probe compound based on tetrastyrene was designed to introduce D-galactose residues, and the trans and cis isomers were successfully isolated by reverse-phase mode high-performance liquid chromatography, using them to β- in senescent cells. Gal reacts, and the hydrolysate acts on the lysosomes, raising the reactive oxygen level, and achieving a targeted method of removing senescent cells.
Targeted clearance of senescent cells and effective treatment of osteoporosis were achieved. Both trans and cis isomers showed synergistic clearance effects, significantly improving the therapeutic effect.
Smart Images

Figure CN119080850A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a fluorescent probe compound for targeting and removing senescent cells, a preparation method of the probe compound and applications thereof. Background Art
[0002] With the progress of aging, the mechanism of aging and anti-aging related treatments have gradually become research hotspots. With the deepening of research, it is found that the aging of the body has obvious heterogeneity, and different organs and cell types have unique aging phenotypes. Conventional methods of removing senescent cells have gradually revealed their drawbacks, mainly reflected in their weak broad spectrum and low specificity. Some studies have designed indicator molecules that specifically identify senescent cells by targeting aging markers. Among the many markers, β-galactosidase is secreted in large quantities by lysosomes and aggregated in the cytoplasm, and is the most commonly used marker.
[0003] Tetraphenylethylene (TPE) and its derivatives are widely used in biological imaging and diagnosis and treatment due to their unique aggregation-induced emission properties. Although fluorescent probes based on TPE and introducing D-galactose residues, a recognition group of β-galactosidase (β-Gal), have been studied, such probes usually only have imaging capabilities but not clearance capabilities.
[0004] Therefore, it is of great significance to design and synthesize a class of probe compounds with diagnostic and therapeutic functions, especially fluorescent probe compounds. Summary of the invention
[0005] In view of the shortcomings of existing anti-aging drugs, such as poor recognition of senescent cells in the body, low sensitivity, and lack of clearance ability, an object of the present invention is to provide a probe compound, especially a fluorescent probe compound, for targeting and clearing senescent cells as an anti-aging prodrug, and use it for the treatment of osteoporosis.
[0006] Another object of the present invention is to provide a preparation method of the above-mentioned probe compound (especially fluorescent probe compound) and its application.
[0007] The present invention is achieved through the following technical solutions:
[0008] 1. A probe compound, the structure of which is represented by Formula I:
[0009]
[0010] in represents cis and trans isomers, and R1, R2, R3, R4, R5 and R6 each independently represent H, C1-C6 alkyl, C2-C6 alkenyl or C1-C6 alkoxy.
[0011] Preferably, the probe compound is selected from at least one of the compounds represented by the following formula I-1 and formula I-2:
[0012]
[0013] Preferably, R1, R2, R3, R4, R5 and R6 are all H.
[0014] 2. A method for preparing the probe compound, comprising the following steps:
[0015] 1) reacting a compound represented by formula 1 with a compound represented by formula 2 to obtain a compound represented by formula II;
[0016]
[0017] as well as
[0018] 2) reacting the compound represented by formula II with sodium methoxide to obtain the compound represented by formula I,
[0019]
[0020] Preferably, step 1) comprises:
[0021] 1-1) under a nitrogen atmosphere, mixing a compound represented by formula 2 with a base and anhydrous sodium sulfate, and reacting in an organic solvent to obtain a reactant; and
[0022] 1-2) Add the compound represented by formula 1 to the reactant, continue the reaction and purify to obtain the compound represented by formula II.
[0023] Preferably, in step 1-1),
[0024] The base is cesium carbonate;
[0025] The molar ratio of the compound represented by formula 2: the compound represented by formula 1: the base: the anhydrous sodium sulfate is 2-3: 1-2: 4-5: 4-5;
[0026] The organic solvent is selected from at least one of anhydrous acetonitrile and anhydrous dichloromethane;
[0027] The reaction temperature is 20°C-25°C, and the reaction time is 12-18h.
[0028] Preferably, in step 2),
[0029] The molar ratio of the compound represented by formula II to sodium methoxide is (0.5-1):(2.5-5), or
[0030] The reaction temperature is 0-5°C and the reaction time is 1-5h.
[0031] Preferably, the preparation method further comprises 3) separating the compound represented by formula I into cis isomers and trans isomers using high performance liquid chromatography in reverse phase mode.
[0032] 3. Use of the probe compound in the preparation of anti-aging prodrugs for targeting and eliminating senescent cells.
[0033] 4. Use of the probe compound in the preparation of a drug for treating osteoporosis.
[0034] Compared with the prior art, the present invention has the following technical effects and advantages:
[0035] The present invention uses tetraphenylethylene as the basic structure, introduces D-galactose residues, obtains a probe compound (TPE-Gal) of mixed configuration, and further uses high performance liquid chromatography (HPLC) in reverse phase mode to successfully separate the trans (compound represented by formula I-1) and cis isomers (compound represented by formula I-2) of TPE-Gal. After the trans and cis isomers of TPE-Gal react with β-Gal in senescent cells, the hydrolysis product TPE-OH acts on lysosomes, increases the level of reactive oxygen in the cells, and causes apoptosis of senescent cells, thereby achieving targeting and clearing senescent cells. In in vivo studies, both trans and cis TPE-Gal have good therapeutic effects on age-related osteoporosis.
[0036] Particularly unexpectedly, the trans and cis isomers of TPE-Gal also showed a synergistic clearance effect on senescent cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 The synthetic route diagram of the compound represented by Formula I and the compound represented by Formula II in Example 1 of the present invention.
[0038] Figure 2 A: Fluorescence images of the trans isomer (trans TPE-Gal) and cis isomer (cis TPE-Gal) of TPE-Gal in Example 2 of the present invention targeting senescent cells; B: Fluorescence image of young cells labeled with PKH67 in the control example; and C: a merged image of the fluorescence images of A and B;
[0039] (TPE-Gal recognizes senescent cells and emits red fluorescence; PKH67 marks young cells in green).
[0040] Figure 3 The bar graph shows the change in cell viability over time after treating a senescent cell population with the trans isomer (trans TPE-Gal) and cis isomer (cis TPE-Gal), respectively.
[0041] Figure 4 CT images of A: healthy mice (SAMR1); B: disease group mice (SAMP6); C: mice treated with the trans isomer of TPE-Gal (trans TPE-Gal); and D: mice treated with the cis isomer of TPE-Gal (cis TPE-Gal).
[0042] Figure 5 A, B, C and D show the comparative results of bone density, bone volume ratio, trabecular number and trabecular spacing of healthy mice (SAMR1), disease mice (SAMP6), mice treated with the trans isomer of TPE-Gal (trans TPE-Gal) and mice treated with the cis isomer of TPE-Gal (cis TPE-Gal), respectively. DETAILED DESCRIPTION
[0043] The present invention is further illustrated below by describing specific implementation schemes, but this is not a limitation of the present invention. Those skilled in the art can make various modifications or improvements based on the basic idea of the present invention, but as long as they do not deviate from the basic idea of the present invention, they are all within the scope of the present invention.
[0044] In the first aspect, the present invention provides a probe compound, the structure of which is shown in Formula I:
[0045]
[0046] in represents cis and trans isomers, and R1, R2, R3, R4, R5 and R6 each independently represent H, C1-C6 alkyl, C2-C6 alkenyl or C1-C6 alkoxy.
[0047] Preferably, the probe compound is a mixed configuration fluorescent probe compound, and its structural formula is represented by Formula I. More preferably, the probe compound is selected from at least one of the trans and cis isomers of TPE-Gal. That is, the probe compound can be selected from at least one of the following Formulas I-1 and I-2:
[0048]
[0049] In a preferred embodiment, R1, R2, R3, R4, R5 and R6 are all H. In this case, the compound represented by formula I is as follows:
[0050]
[0051] In various embodiments of the present invention, R1, R2, R3, R4, R5 and R6 may each independently represent H, C1-C6 alkyl, C2-C6 alkenyl or C1-C6 alkoxy.
[0052] In this article, the "-" connected to R1, R2, R3, R4, R5 and R6 means that one or more groups are connected to the benzene ring through a chemical single bond, but the connection position and the number of R1, R2, R3, R4, R5 and R6 are not limited. In other words, R1, R2, R3, R4, R5 and R6 can be 1 or more, and the maximum number depends on the position available for connection on the benzene ring.
[0053] Preferably, when at least one of R1, R2, R3, R4, R5 and R6 is not hydrogen, the structure of Formula 1 is as follows:
[0054]
[0055] Herein, the C1-C6 alkyl group refers to an alkyl group having 1 to 6 carbon atoms, such as methyl, ethyl, isopropyl, n-propyl, n-butyl, n-pentyl, n-hexyl, 2-methylpentyl, and the like.
[0056] The C2-C6 alkenyl group refers to an alkenyl group having 2 to 6 carbon atoms, for example, ethenyl, propenyl, 1-butenyl, 2-butenyl, 1-pentenyl, 2-pentenyl, 1-hexenyl and the like.
[0057] Herein, the C1-C6 alkoxy group refers to an alkoxy group having 1 to 6 carbon atoms, for example, methoxy, ethoxy, isopropoxy, n-propoxy, n-butoxy, n-pentoxy, n-hexoxy, 2-methylpentoxy and the like.
[0058] In a second aspect, the present invention provides a method for preparing a probe compound, comprising the steps of:
[0059] 1) reacting a compound represented by formula 1 with a compound represented by formula 2 to obtain a compound represented by formula II;
[0060]
[0061] as well as
[0062] 2) The compound represented by formula II is reacted with sodium methoxide to obtain the compound represented by formula I,
[0063]
[0064] in represents cis and trans isomers, and R1, R2, R3, R4, R5 and R6 each independently represent H, C1-C6 alkyl, C2-C6 alkenyl or C1-C6 alkoxy.
[0065] Similarly, in Formula 1, Formula 2 and Formula II, when at least one of R1, R2, R3, R4, R5 and R6 is not hydrogen, R1, R2, R3, R4, R5 and R6 are also in the meta position relative to other groups on the benzene ring.
[0066] Preferably, step 1) may include:
[0067] 1-1) under a nitrogen atmosphere, mixing a compound represented by Formula 2 with a base and anhydrous sodium sulfate, and reacting in an organic solvent to obtain a reactant;
[0068] 1-2) Add the compound represented by formula 1 to the reactants, continue the reaction and purify to obtain the compound represented by formula II.
[0069] In a specific embodiment, the operation of step 1-1) of the above method is: under a nitrogen atmosphere, the compound represented by formula 2 (hexopyranoside-4-(bromomethyl)phenyl-2,3,4,6-tetraacetate) is first mixed with a base and anhydrous sodium sulfate, stirred in an organic solvent for reaction, and then the compound represented by formula 1 TPE-OH (R2, R3, R4, R5 and R6 are all H) is added, and the stirring reaction is continued for 12 hours, and after the reaction, the reaction is filtered and concentrated in vacuo. Using dichloromethane / methanol as the eluent, column chromatography is used to obtain the compound represented by formula II.
[0070] In step 1-1), the base may be cesium carbonate, potassium carbonate and sodium carbonate.
[0071] Preferably, in the above step 1-1), the molar ratio of the compound of formula 2: the compound of formula 1: the base: anhydrous sodium sulfate is 2-3: 1-2: 4-5: 4-5. The molar ratio of the compound of formula 2: the compound of formula 1: the base: anhydrous sodium sulfate is more preferably 2: 1: 4: 4.
[0072] Preferably, the organic solvent is selected from at least one of anhydrous acetonitrile and anhydrous dichloromethane.
[0073] The reaction temperature of step 1-1) can be 20° C.-25° C. The reaction time of step 1-1) can be 12-18 hours. More preferably, the reaction temperature of step 1-1) can be 25° C. and the reaction time can be 12 hours.
[0074] The specific operation of step 1-2) of the above method can be: dissolve the compound TPE-OAc (30 mg, 0.032 mmol) shown in formula II in dry methanol (5 mL) at 0°C under nitrogen protection, and add sodium methoxide (8.64 mg, 0.16 mmol) thereto. The reaction mixture is stirred at 0°C for 1 hour. Then the solvent is evaporated with CH2Cl2 (3×50 mL), and then washed with saturated NH4Cl solution. The organic layer is dried with anhydrous sodium sulfate, concentrated in vacuo, and the crude product is purified by semi-preparative high performance liquid chromatography, with the mobile phase being eluent A (water containing 0.1% trifluoroacetic acid) and eluent B (acetonitrile containing 0.1% trifluoroacetic acid), to obtain the compound shown in formula I.
[0075] Preferably, in step 2), the molar ratio of the compound represented by formula II to sodium methoxide is (0.5-5):(2.5-25), preferably 1:5.
[0076] The reaction temperature of step 2) is 0-5°C, preferably 0°C, and the reaction time is 1-5h, preferably 1h.
[0077] In one embodiment, a method for preparing a probe compound further comprises 3) separating the compound represented by Formula I into cis isomers and trans isomers using high performance liquid chromatography (HPLC) in reverse phase mode.
[0078] In a third aspect, the present invention provides the use of the above-mentioned probe compound in the preparation of an anti-aging prodrug for targeting and removing senescent cells. In other words, the organic small molecule shown in Formula I can target and remove senescent cells as an anti-aging prodrug.
[0079] In a fourth aspect, the present invention provides use of the above probe compound in the preparation of a medicament for treating osteoporosis.
[0080] The present invention uses tetraphenylethylene as the basic structure and introduces D-galactose residues to obtain a fluorescent probe compound (TPE-Gal), and further uses high-performance liquid chromatography (HPLC) in reverse phase mode to successfully separate the trans (compound represented by formula I-1) and cis isomers (compound represented by formula I-2) of TPE-Gal. After the trans and cis isomers of TPE-Gal react with β-Gal in senescent cells, the hydrolysis product TPE-OH acts on lysosomes, increasing the level of reactive oxygen in the cells and causing apoptosis of senescent cells, thereby achieving targeting and clearing senescent cells. In in vivo studies, both trans and cis TPE-Gal have good therapeutic effects on age-related osteoporosis.
[0081] example
[0082] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods; the reagents, materials, etc. used in the following examples are all available from commercial channels unless otherwise specified.
[0083] The TPE-OH (mixed configuration) used in the following examples was purchased from Shanghai BiDe Co., Ltd.
[0084] Preparation Example - The synthetic chemical reaction flow chart of the compound represented by Formula II (R1, R2, R3, R4, R5 and R6 are all H) is as follows Figure 1 As shown, the specific reaction step conditions are as follows:
[0085] The intermediate product TPE-OAc (a compound represented by formula II, wherein R1, R2, R3, R4, R5 and R6 are all H) was synthesized by the following method: 4-(bromomethyl)phenyl-2,3,4,6-tetraacetate (400 mg, 0.77 mmol), Cs2CO3 (495 mg, 1.52 mmol) and Na2SO4 (216 mg, 1.52 mmol) were dissolved in 5 mL of anhydrous acetonitrile under nitrogen. TPE-OH (190 mg, 0.38 mmol) was added to the mixture at room temperature and stirred overnight. After the reaction, the mixture was filtered and concentrated in vacuo. TPE-OAc (227 mg, 63.7%) was obtained by column chromatography using dichloromethane / methanol as the eluent;
[0086] The data for the confirmation of the structure of TPE-OAc are as follows:
[0087] 1 H NMR (400MHz, CDCl3, 298K): δ7.56-7.52(m,1H),7.49-7.32(m,6H),7.22-6.88(m,18H),6.74-6.69(m,2H),5.52-5.46(m,2H),5.11(d,J= 12.0Hz,1H),5.08-5.02(m,1H),4.92(d,J=4.0Hz,2H),4.26-4.14(m,2H),4.06(br,1H),2.19(s,3H),2.06(t,J=4.0Hz,6H),2.02(s,3H).
[0088] 13C NMR (101MHz, CDCl3, 298K): δ174.38,170.33,170.22,170.10,169.36,158.00,156.82,156.78,149.25,143.12,143.09,143.01,142.9 6,142.85,138.76,138.73,136.16,135.66,135.58,133.66,133.61,132.65,132.57,132.48,132.44,131.81,131.65,131.39,131.34 ,131.29,130.43,130.40,130.06,129.99,129.22,129.16,128.79,128.75,128.10,127.97,127.89,127.72,127.12,126.94,126.81,117.09,117.06,114.17,114.12,114.01,99.77,99.74,80.78,71.09,70.85,69.47,69.41,68.70,66.89,61.35,20.71,20.64,20.56;
[0089] High resolution mass spectrometry: calculated value is C 57 H 48 N2NaO 11 [M+Na] + :959.3150, mass spectrum peak position: 959.3147;
[0090] From the above, we can see that the product structure is correct.
[0091] Example 1
[0092] The TPE-OAc (30 mg, 0.032 mmol) obtained in the preparation example was dissolved in dry methanol (5 mL) at 0°C under nitrogen protection, and sodium methoxide (8.64 mg, 0.16 mmol) was added thereto. The reaction mixture was stirred at 0°C for 1 hour. The solvent was then evaporated with CH2Cl2 (3×50 mL), and then washed with saturated NH4Cl solution. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by semi-preparative high performance liquid chromatography to obtain a compound of formula I with a mixed configuration.
[0093] Example 2
[0094] Semi-preparative high performance liquid chromatography (column type: Bio-Bond C8 column (pore size The compound of formula I obtained in Example 1 was purified by HPLC (ID 2.1×150mm) method, and trans-TPE-Gal (5.10 mg, 19.8%) and cis-TPE-Gal (4.97 mg, 19.3%) were obtained using eluent A (water containing 0.1% trifluoroacetic acid).
[0095] The structural confirmation data are as follows:
[0096] Trans-TPE-Gal: 1 H NMR(700MHz, DMSO-d6)δ7.63(t,J=7.4Hz,1H),7.55(t,J=7.8Hz,2H),7.41-7.39(m,2H),7.35-7.32(m,2H),
[0097] 7.24-7.20(m,4H),7.17-7.14(m,4H),7.10-7.08(m,2H),7.05-7.01(m,4H),6.97-6.96(m,2H),6.89-6.87(m,2H),6.80-6.7 8(m,2H),4.92(s,2H),4.82(d,J=7.7Hz,1H),3.69(d,J=3.4Hz,1H),3.58-3.53(m,5H),3.49-3.47(m,2H),3.41-3.39(m,2H).
[0098] 13 C NMR(176MHz,DMSO-d6)δ173.37,157.16,148.09,142.72,142.56,142.08 ,138.45,135.85,134.81,133.58,132.36,131.87,130.86,130.72,130. 59,130.03,129.84,129.36,128.71,128.09,127.74,126.86,126.71,11 6.01,113.95,100.82,81.14,75.38,73.19,70.14,68.76,68.01,60.24;
[0099] High resolution mass spectrometry: calculated value is C 49 H 40 ClN2O7[M-Cl]-:803.2530, mass spectrum peak position: 803.2527.
[0100] From the above, we can see that the product structure is correct.
[0101] Cis-TPE-Gal: 1H NMR(700MHz, DMSO-d6)δ7.63(t,J=7.4Hz,1H),7.55(t,J=7.2Hz,2H),7.45-7.42(m,2H),7.35-7.32(m,2H),
[0102] 7.30-7.27(m,2H),7.17-7.11(m,8H),7.04-7.01(m,2H),7.01-6.99(m,4H),6.86-6.85(m,2H),6.80-6.79(m,2H), 4.92(s,2H),4.83(d,J=7.7Hz,1H),3.70(d,J=3.3Hz,1H),3.58-3.54(m,3H),3.51-3.47(m,1H),3.42-3.40(m,1H).
[0103] 13 C NMR (176MHz, DMSO-d6) δ173.44,157.36,157.17,148.15,142.77,142.46,142. 10,138.46,135.87,134.72,133.65,132.38,131.98,130.89,130.62,130.09, 129.97,129.83,129.31,128.73,127.95,127.73,126.77,126.63,116.05,114.29,114.20,113.97,100.80,81.18,75.39,73.19,70.15,68.85,68.01,60.24.
[0104] High resolution mass spectrometry: calculated value is C 49 H 40 ClN2O7[M-Cl]-:803.2530, mass spectrum peak position: 803.2532.
[0105] From the above, we can see that the product structure is correct.
[0106] Example 3
[0107] The intermediate product TPE-OAc (a compound represented by Formula II, wherein R1 is a meta-methyl group and R2-R6 are hydrogen) is synthesized by the following method:
[0108] Under nitrogen conditions, methyl-substituted hexapyranoside-4-(bromomethyl)phenyl-2,3,4,6-tetraacetate (400 mg, 0.73 mmol), Cs2CO3 (495 mg, 1.52 mmol) and Na2SO4 (216 mg, 1.52 mmol) were dissolved in 5 mL of anhydrous acetonitrile. At room temperature, TPE-OH (190 mg, 0.38 mmol) was added to the mixture and stirred overnight. After the reaction, the mixture was filtered and concentrated in vacuo. TPE-MeOAc (248 mg, 69.7%) was obtained by column chromatography using dichloromethane / methanol as the eluent;
[0109] The obtained TPE-MeOAc (wherein R1 is meta-methyl and R2-R6 is hydrogen) (30 mg, 0.032 mmol) was dissolved in dry methanol (5 mL) at 0°C under nitrogen protection, and sodium methoxide (8.64 mg, 0.16 mmol) was added thereto. The reaction mixture was stirred at 0°C for 1 hour. The solvent was then evaporated with CH2Cl2 (3×50 mL) and then washed with saturated NH4Cl solution. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by semi-preparative high performance liquid chromatography to obtain the compound of Example 3 of mixed configuration.
[0110] Example 4
[0111] The intermediate product MeO-TPE-OAc (a compound represented by Formula II, wherein R2 is a meta-methoxy group, and R1 and R3-R6 are hydrogen) is synthesized by the following method:
[0112] Under nitrogen conditions, 4-(bromomethyl)phenyl-2,3,4,6-tetraacetate (400 mg, 0.77 mmol), Cs2CO3 (495 mg, 1.52 mmol) and Na2SO4 (216 mg, 1.52 mmol) were dissolved in 5 mL of anhydrous acetonitrile. At room temperature, MeO-TPE-OH (wherein R2 is meta-methoxy and R3-R6 are hydrogen) (190 mg, 0.35 mmol) was added to the mixture and stirred overnight. After the reaction, the mixture was filtered and concentrated in vacuo. MeO-TPE-OAc (218 mg, 63.4%) was obtained by column chromatography using dichloromethane / methanol as the eluent;
[0113] The obtained MeO-TPE-OAc (30 mg, 0.031 mmol) was dissolved in dry methanol (5 mL) at 0°C under nitrogen protection, and sodium methoxide (8.64 mg, 0.16 mmol) was added thereto. The reaction mixture was stirred at 0°C for 1 hour. The solvent was then evaporated with CH2Cl2 (3×50 mL) and then washed with saturated NH4Cl solution. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by semi-preparative high performance liquid chromatography to obtain the compound of Example 4 of mixed configuration.
[0114] Comparative Example 1
[0115]
[0116] Under nitrogen, 4-(bromomethyl)phenyl-2,3,4,6-tetraacetate (400 mg, 0.77 mmol), Cs2CO3 (495 mg, 1.52 mmol) and Na2SO4 (216 mg, 1.52 mmol) were dissolved in 5 mL of anhydrous acetonitrile. At room temperature, 4-(1,2,2-triphenylvinyl)phenol (130 mg, 0.38 mmol) was added to the mixture and stirred overnight. After the reaction, the mixture was filtered and concentrated in vacuo. TPE-Ac (188 mg, 66.4%) was obtained by column chromatography using dichloromethane / methanol as the eluent.
[0117] The structural confirmation data of TPE-Ac are as follows:
[0118] 1 H NMR (400MHz, CDCl3, 298K): δ7.46-7.30 (m, 17H), 6.99-6.89 (m, 6H), 6.39 (d, J = 4.0Hz, 1H), 5.95-5.8 6(m,1H),5.29-5.24(m,2H),5.14(s,2H),4.78(br,1H),4.35-4.29(m,2H),2.04(s,3H),2.02(s,9H);
[0119] 13 C NMR (100MHz, CDCl3, 298K): δ170.2,158.2,156.3,140.0,129.4,128.8,128.6,127.9,114.6,105.5,74.8,70.8,70.3,69.3,62.7,21.0,20.7;
[0120] High resolution mass spectrometry: calculated value is C 47 H 44 O 11 [M] +:784.2890, mass spectrum peak position: 784.2884;
[0121] From the above, we can see that the product structure is correct.
[0122] TPE-Ac (25 mg, 0.032 mmol) obtained in the preparation example was dissolved in dry methanol (5 mL) at 0°C under nitrogen protection, and sodium methoxide (8.64 mg, 0.16 mmol) was added thereto. The reaction mixture was stirred at 0°C for 1 hour. The solvent was then evaporated with CH2Cl2 (3×50 mL), and then washed with saturated NH4Cl solution. The organic layer was dried over anhydrous sodium sulfate and concentrated in vacuo. The crude product was purified by semi-preparative HPLC to obtain a compound of formula III (9.99 mg,
[0123] 50.6%).
[0124] The structural confirmation data of the compound of formula III are as follows:
[0125] 1 H NMR(400MHz,DMSO-d6,298K):δ7.47-7.33(m,17H),
[0126] 6.90-6.80(m,6H),5.80(d,J=3.4Hz,1H),5.17(s,2H),4.88-4.78(br,4H),4.51(t,J=4.35-3.91(m,5H);
[0127] 13 C NMR (100MHz, DMSO-d6, 298K): δ158.7, 157.9, 141.3, 140.2, 132.3, 128.9, 128.6, 127.9, 114.2, 73.4, 81.5, 76.0, 73.4, 71.5, 62.2;
[0128] High resolution mass spectrometry: calculated value is C 39 H 36 O7[M] + :616.2473, mass spectrum peak position: 616.2461;
[0129] From the above, we can see that the product structure is correct.
[0130] Comparative Example 2
[0131] A mixture of a compound of formula III and a compound of the following formula IV (mass ratio 1:1).
[0132]
[0133] The compound of formula IV was purchased from Henan Pusai Chemical Products Co., Ltd.
[0134] Test Case
[0135] Test Example 1- Targeting of Aged Mesenchymal Stem Cells
[0136] A co-culture system was used to detect the targeting effect of trans-TPE-Gal and cis-TPE-Gal of Example 2 on aging mesenchymal stem cells. The young cells were first stained green with PKH67 (Solebo, D0031), and then inoculated with aging cells in a confocal dish (NEST). After 24 hours of attachment, the old culture medium was removed and replaced with culture medium solutions containing 10 μM trans-TPE-Gal and cis-TPE-Gal, respectively. The culture medium was incubated in an incubator for 1 hour, and then replaced with fresh culture medium without drugs. Images were collected under a FV3000 (Olympus) microscope. The excitation wavelength of TPE-Gal was 405 nm, and the emission wavelength was 550 nm (red). Figure 2 As shown, the green young cells and the TPE-Gal-recognized senescent red cells are clearly distinguishable.
[0137] Test Example 2- Hidden Toxicity to Aged Mesenchymal Stem Cells
[0138] CCK-8 (Cell Counting Kit-8) was used to analyze the clearing effects of the trans-TPE-Gal and cis-TPE-Gal of Comparative Examples 1-2, Example 2, and the compounds of Examples 3-4 on the population of human aging mesenchymal stem cells. CCK-8 contains WST (water-soluble tetrazolium salt, chemical name: 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfonylbenzene)-2H-tetrazole monosodium salt), which is reduced by dehydrogenases in cells under the action of the electron carrier 1-methoxy-5-methylphenazinium dimethyl sulfate (1-Methoxy PMS) to a highly water-soluble yellow formazan product (Formazan dye), which absorbs at 450nm. The amount of formazan generated is proportional to the number of living cells, so the absorbance at 450nm can be used to analyze the cell viability. Specifically, 23 generations of mesenchymal stem cells can be measured at 5×10 4 / mL density was inoculated in a 96-well plate. After incubation for 24 hours, the original culture medium in each well was replaced with the culture medium solution containing 10 μM of Comparative Example 1, the mixture of Comparative Example 2, the trans-TPE-Gal and cis-TPE-Gal of Example 2, and Examples 3-4, respectively. Incubate in the incubator for 4 hours, 6 hours, 12 hours and 24 hours, respectively, and replace all the drug-containing solutions with fresh culture medium at the above time points. After 24 hours, the culture medium in each well was replaced with a CCK-8 solution containing 10 μL (with 100 μL culture medium as solvent), and then returned to the incubator. After incubation for 1 hour, the absorbance value of each well solution at 450 nm was read with an enzyme marker. The cell viability (VR) was calculated according to the following formula: VR = A / A0 100%, where A is the absorbance of the experimental group, and A0 is the absorbance of cells without any treatment in the serum-added culture medium.
[0139] The hidden toxicity of the compound of Example 2 of the present invention to the human aging mesenchymal stem cell population is as follows Figure 3 As shown. Figure 3 At a single administration concentration (10 μM), both trans- and cis-TPE-Gal had targeted dark toxicity to the senescent cell population. After 24 hours of action of trans-TPE-Gal and cis-TPE-Gal, the clearance rates of the senescent cell population were 48.4% and 47%, respectively.
[0140] The dark toxicity of Examples 3-4 and Comparative Examples 1-2 on the human senescent mesenchymal stem cell population after 24 hours of action is shown in Table 1 below.
[0141] Table 1
[0142] Compound Senescent cell clearance rate Example 3 13.7% Example 4 19.5% Comparative Example 1 1.1% Comparative Example 2 1.5%
[0143] The results show that the compound of Comparative Example 1 and the mixture of Comparative Example 2 have almost no clearing effect on human aging mesenchymal stem cells. In contrast, the compound of Formula I of the present invention shows a synergistic clearing effect on human aging mesenchymal stem cells. In particular, the trans-TPE-Gal and cis-TPE-Gal of Example 2 show significantly better synergistic clearing effects.
[0144] Test Example 3-Therapeutic Effect on Aging-Related Osteoporosis
[0145] SAMP6 mice (senescence-accelerated mouse-prone 6mouse, a premature aging model mouse with osteoporosis as the phenotype) were selected as the in vivo application model. This mouse began to experience bone loss at 4 months of age, and the osteoporosis phenotype was most typical at 6 months of age. Therefore, trans-TPE-Gal and cis-TPE-Gal were used in vivo starting at 4 months of age to intervene in bone loss by removing senescent cells.
[0146] At 4 months of age, the intervention group SAMP6 mice were injected with 50 μM, 200 μL of trans-TPE-Gal or cis-TPE-Gal of Example 2 through the tail vein once a week for 2 months; SAMR1 mice were used as the healthy group; SAMP6 mice injected with 200 μL of PBS were used as the disease group, and injected once a week for 2 months. The femurs of the mice were collected and fixed for micro CT scanning. Figure 4 As shown in A, B, C and D, the images of different cross sections show the ability of TPE-Gal to rescue bone density. Figure 5 As shown in A, B, C, and D, the bone density, bone volume ratio, trabecular number, and trabecular spacing of each group were evaluated. The results showed that compared with the disease group SAMP6 mice, the cis-trans isomers of TPE-Gal significantly increased the bone density, bone volume ratio, and trabecular number, and reduced the trabecular spacing, thus proving that the cis-trans isomers of TPE-Gal have a good therapeutic effect on osteoporosis.
[0147] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the embodiments of the present invention, rather than to limit them. Although the present invention has been described in detail with reference to the above embodiments, those skilled in the art should understand that they can still modify the technical solutions recorded in the above embodiments, or replace some of the technical features therein by equivalents; and these modifications or replacements do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention. Any changes or replacements that can be easily thought of by those skilled in the art within the technical scope disclosed in the present invention should be covered within the protection scope of the present invention.
Claims
1. A probe compound, characterized in that The structure of the probe compound is represented by Formula I: in represents cis and trans isomers, and R1, R2, R3, R4, R5 and R6 each independently represent H, C1-C6 alkyl, C2-C6 alkenyl or C1-C6 alkoxy.
2. The probe compound according to claim 1, characterized in that The probe compound is selected from at least one of the compounds represented by the following formula I-1 and formula I-2:
3. The probe compound according to claim 1 or 2, characterized in that R1, R2, R3, R4, R5 and R6 are all H.
4. A method for preparing the probe compound according to any one of claims 1 to 3, characterized in that The steps include: 1) reacting a compound represented by formula 1 with a compound represented by formula 2 to obtain a compound represented by formula II; as well as 2) reacting the compound represented by formula II with sodium methoxide to obtain the compound represented by formula I, 5. The method according to claim 4, characterized in that: Step 1) includes: 1-1) under a nitrogen atmosphere, mixing a compound represented by formula 2 with a base and anhydrous sodium sulfate, and reacting in an organic solvent to obtain a reactant; and 1-2) Add the compound represented by formula 1 to the reactant, continue the reaction and purify to obtain the compound represented by formula II.
6. The method according to claim 5, characterized in that: In step 1-1), The base is cesium carbonate; The molar ratio of the compound represented by formula 2: the compound represented by formula 1: the base: the anhydrous sodium sulfate is 2-3: 1-2: 4-5: 4-5; The organic solvent is selected from at least one of anhydrous acetonitrile and anhydrous dichloromethane; The reaction temperature is 20°C-25°C, and the reaction time is 12-18h.
7. The method according to any one of claims 4 to 6, characterized in that: In step 2), The molar ratio of the compound represented by formula II to sodium methoxide is (0.5-1):(2.5-5), or The reaction temperature is 0-5°C and the reaction time is 1-5h.
8. The method according to any one of claims 4 to 6, characterized in that: The method further comprises 3) separating the compound represented by formula I into cis isomers and trans isomers using high performance liquid chromatography in reverse phase mode.
9. Use of the probe compound according to any one of claims 1 to 3 in the preparation of an anti-aging prodrug for targeting and eliminating senescent cells.
10. Use of the probe compound according to any one of claims 1 to 3 in the preparation of a medicament for treating osteoporosis.
